Tardive Dyskinesia Epidemiology

Tardive Dyskinesia Insights and Trends

• The increasing and off-label use of dopamine receptor antagonists (DRAs) across schizophrenia, bipolar disorder, depression, anxiety, and insomnia continues to expand the at-risk population for tardive dyskinesia, with a growing proportion of cases linked to newer-generation antipsychotics.
• Tardive dyskinesia prevalence and antipsychotic exposure increase substantially with age, particularly among elderly and long-term care populations, where polypharmacy, cognitive impairment, and prolonged antipsychotic use further increase disease burden.
• Reported prevalence of tardive dyskinesia varies considerably across regions however, limited real-world surveillance, lack of incidence data, and inconsistent screening practices continue to contribute to significant underdiagnosis and underestimation of the overall disease burden.

Tardive Dyskinesia Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Tardive Dyskinesia : ~430,500
• 2036 Projected Diagnosed Prevalent Cases of Tardive Dyskinesia : ~513,500
• Tardive Dyskinesia Growth Rate (2026–2036): ~1.6% CAGR

DelveInsight's ‘Tardive Dyskinesia– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Tardive Dyskinesia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Tardive Dyskinesia Understanding and Diagnosis Algorithm

Tardive Dyskinesia Overview and Diagnosis

Tardive dyskinesia is a drug-induced movement disorder characterized by involuntary, repetitive movements involving the face, mouth, tongue, and jaw, with possible involvement of the trunk and limbs. It is primarily associated with long-term exposure to dopamine receptor–blocking agents (DRBAs), particularly antipsychotics and certain antiemetics such as metoclopramide. The condition is often chronic and persistent, continuing even after drug withdrawal, and can significantly impair functioning and quality of life. Proposed mechanisms include dopamine receptor supersensitivity, oxidative stress, and GABAergic dysfunction. Despite increasing awareness, tardive dyskinesia remains a major clinical burden, and currently available therapies, including VMAT2 inhibitors (valbenazine, deutetrabenazine), provide mainly symptomatic relief, highlighting an ongoing unmet need.

Further details are provided in the report.

Tardive Dyskinesia Diagnosis

Tardive dyskinesia is diagnosed clinically based on history of dopamine receptor–blocking agent (DRBA) exposure and the presence of characteristic involuntary movements, but remains underdiagnosed in routine practice. The DSM-5-TR defines it as a medication-induced movement disorder after = 3 months of antipsychotic exposure (or = 1 month in elderly patients), while the Schooler–Kane criteria and AIMS scale support confirmation and severity assessment. It must be differentiated from other drug-induced movement disorders such as parkinsonism, akathisia, dystonia, and tremor, as well as neuroleptic malignant syndrome, with key distinction being its onset after long-term exposure and potential persistence after drug withdrawal, making accurate diagnosis critical for appropriate management.

Further details are provided in the report.

Tardive Dyskinesia Epidemiology

Key Findings from Tardive Dyskinesia Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of tardive dyskinesia in the 7MM were ~ 1,777,000.
• The United States accounted for ~40% of the total antipsychotic drug user population across the 7MM in 2025.
• The United States accounted for ~40% of the total population receiving =3 months of antipsychotic therapy across the 7MM in 2025, making it one of the major contributing markets.
• Among the EU4 and the UK, Germany accounted for the highest prevalent cases of tardive dyskinesia in 2025, whereas the UK reported the lowest number of incident cases during the same year.
• The majority of diagnosed prevalent cases of tardive dyskinesia in the United States in 2025 were classified as moderate-to-severe, accounting for approximately ~60% of cases, while mild cases represented nearly ~40% of the total diagnosed prevalent population for each severity class.

Scope of the Report

• The report covers a segment of a descriptive overview of tardive dyskinesia, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Tardive Dyskinesia Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of tardive dyskinesia? What will be the growth opportunities across the 7MM concerning the patient population with tardive dyskinesia?
• What is the historical and forecasted tardive dyskinesia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.